These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 15115380

  • 1. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
    Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, Steensma RW, Strizki JM, Baroudy BM, Cox K, Lachowicz J, Varty G, Watkins R.
    J Med Chem; 2004 May 06; 47(10):2405-8. PubMed ID: 15115380
    [Abstract] [Full Text] [Related]

  • 2. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist.
    Tagat JR, Steensma RW, McCombie SW, Nazareno DV, Lin SI, Neustadt BR, Cox K, Xu S, Wojcik L, Murray MG, Vantuno N, Baroudy BM, Strizki JM.
    J Med Chem; 2001 Oct 11; 44(21):3343-6. PubMed ID: 11585438
    [Abstract] [Full Text] [Related]

  • 3. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
    Seto M, Aikawa K, Miyamoto N, Aramaki Y, Kanzaki N, Takashima K, Kuze Y, Iizawa Y, Baba M, Shiraishi M.
    J Med Chem; 2006 Mar 23; 49(6):2037-48. PubMed ID: 16539392
    [Abstract] [Full Text] [Related]

  • 4. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N, Solomon K, Zhou N, Wang KH, Garlapati V, Thomas B, Li Y, Covington M, Baribaud F, Erickson-Viitanen S, Czerniak P, Contel N, Liu P, Burn T, Hollis G, Yeleswaram S, Vaddi K, Xue CB, Metcalf B, Friedman S, Scherle P, Newton R.
    J Pharmacol Exp Ther; 2011 Jul 23; 338(1):228-39. PubMed ID: 21459966
    [Abstract] [Full Text] [Related]

  • 5. Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.
    Palani A, Shapiro S, Clader JW, Greenlee WJ, Cox K, Strizki J, Endres M, Baroudy BM.
    J Med Chem; 2001 Oct 11; 44(21):3339-42. PubMed ID: 11585437
    [Abstract] [Full Text] [Related]

  • 6. Facile synthesis of 4-substituted-4-aminopiperidine derivatives, the key building block of piperazine-based CCR5 antagonists.
    Jiang XH, Song YL, Long YQ.
    Bioorg Med Chem Lett; 2004 Jul 16; 14(14):3675-8. PubMed ID: 15203141
    [Abstract] [Full Text] [Related]

  • 7. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.
    Shen DM, Shu M, Willoughby CA, Shah S, Lynch CL, Hale JJ, Mills SG, Chapman KT, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ, Lyons K, Pivnichny JV, Kwei GY, Carella A, Carver G, Holmes K, Schleif WA, Danzeisen R, Hazuda D, Kessler J, Lineberger J, Miller MD, Emini EA.
    Bioorg Med Chem Lett; 2004 Feb 23; 14(4):941-5. PubMed ID: 15012998
    [Abstract] [Full Text] [Related]

  • 8. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
    Imamura S, Nishikawa Y, Ichikawa T, Hattori T, Matsushita Y, Hashiguchi S, Kanzaki N, Iizawa Y, Baba M, Sugihara Y.
    Bioorg Med Chem; 2005 Jan 17; 13(2):397-416. PubMed ID: 15598561
    [Abstract] [Full Text] [Related]

  • 9. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors.
    Debnath AK.
    J Med Chem; 2003 Oct 09; 46(21):4501-15. PubMed ID: 14521412
    [Abstract] [Full Text] [Related]

  • 10. Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile.
    Kazmierski WM, Anderson DL, Aquino C, Chauder BA, Duan M, Ferris R, Kenakin T, Koble CS, Lang DG, McIntyre MS, Peckham J, Watson C, Wheelan P, Spaltenstein A, Wire MB, Svolto A, Youngman M.
    J Med Chem; 2011 Jun 09; 54(11):3756-67. PubMed ID: 21539377
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The discovery of tropane-derived CCR5 receptor antagonists.
    Armour DR, de Groot MJ, Price DA, Stammen BL, Wood A, Perros M, Burt C.
    Chem Biol Drug Des; 2006 Apr 09; 67(4):305-8. PubMed ID: 16629828
    [Abstract] [Full Text] [Related]

  • 16. Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.
    Palani A, Shapiro S, Josien H, Bara T, Clader JW, Greenlee WJ, Cox K, Strizki JM, Baroudy BM.
    J Med Chem; 2002 Jul 04; 45(14):3143-60. PubMed ID: 12086500
    [Abstract] [Full Text] [Related]

  • 17. 1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
    Barber CG, Blakemore DC, Chiva JY, Eastwood RL, Middleton DS, Paradowski KA.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1075-9. PubMed ID: 19171484
    [Abstract] [Full Text] [Related]

  • 18. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.
    Klibanov OM.
    Curr Opin Investig Drugs; 2009 Aug 15; 10(8):845-59. PubMed ID: 19649929
    [Abstract] [Full Text] [Related]

  • 19. Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor.
    Shankaran K, Donnelly KL, Shah SK, Guthikonda RN, MacCoss M, Mills SG, Gould SL, Malkowitz L, Siciliano SJ, Springer MS, Carella A, Carver G, Hazuda D, Holmes K, Kessler J, Lineberger J, Miller MD, Emini EA, Schleif WA.
    Bioorg Med Chem Lett; 2004 Jul 05; 14(13):3419-24. PubMed ID: 15177445
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent.
    Ma D, Yu S, Li B, Chen L, Chen R, Yu K, Zhang L, Chen Z, Zhong D, Gong Z, Wang R, Jiang H, Pei G.
    ChemMedChem; 2007 Feb 05; 2(2):187-93. PubMed ID: 17163560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.